CN101683278A - 锥形有环缝合线 - Google Patents
锥形有环缝合线 Download PDFInfo
- Publication number
- CN101683278A CN101683278A CN200910171682A CN200910171682A CN101683278A CN 101683278 A CN101683278 A CN 101683278A CN 200910171682 A CN200910171682 A CN 200910171682A CN 200910171682 A CN200910171682 A CN 200910171682A CN 101683278 A CN101683278 A CN 101683278A
- Authority
- CN
- China
- Prior art keywords
- stitching thread
- slender bodies
- conical surface
- thread according
- proximal end
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000002904 solvent Substances 0.000 claims abstract description 5
- 239000003292 glue Substances 0.000 claims abstract description 4
- 239000011230 binding agent Substances 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 230000000717 retained effect Effects 0.000 claims description 2
- 150000002118 epoxides Chemical class 0.000 claims 1
- 239000000853 adhesive Substances 0.000 abstract description 2
- 230000001070 adhesive effect Effects 0.000 abstract description 2
- 239000004593 Epoxy Substances 0.000 abstract 1
- 125000003700 epoxy group Chemical group 0.000 abstract 1
- 229920000647 polyepoxide Polymers 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 29
- 239000000463 material Substances 0.000 description 16
- -1 alkylene carbonate Chemical compound 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 229920001577 copolymer Polymers 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 241001597008 Nomeidae Species 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 229930186147 Cephalosporin Natural products 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229940124587 cephalosporin Drugs 0.000 description 4
- 150000001780 cephalosporins Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229960000282 metronidazole Drugs 0.000 description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
- 229960001156 mitoxantrone Drugs 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 235000012771 pancakes Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- IADUEWIQBXOCDZ-VKHMYHEASA-N (S)-azetidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- QPJBONAWFAURGB-UHFFFAOYSA-L Lobenzarit disodium Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1NC1=CC(Cl)=CC=C1C([O-])=O QPJBONAWFAURGB-UHFFFAOYSA-L 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 2
- 229960003644 aztreonam Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 2
- 229960003408 cefazolin sodium Drugs 0.000 description 2
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 229960002770 ertapenem Drugs 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000007499 fusion processing Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- 229950000845 politef Drugs 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000057 synthetic resin Substances 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
- IADUEWIQBXOCDZ-UHFFFAOYSA-N (2S)-azetidine-2-carboxylic acid Natural products OC(=O)C1CCN1 IADUEWIQBXOCDZ-UHFFFAOYSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- LSEFXLGTUCVBPE-UHFFFAOYSA-N 1h-imidazol-2-ylcarbamic acid Chemical class OC(=O)NC1=NC=CN1 LSEFXLGTUCVBPE-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- BOCATKBAKISRLA-UHFFFAOYSA-N 4-propyl-5-pyridin-4-yl-3h-1,3-oxazol-2-one Chemical compound N1C(=O)OC(C=2C=CN=CC=2)=C1CCC BOCATKBAKISRLA-UHFFFAOYSA-N 0.000 description 1
- MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- 108010040512 Clupeine Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- ZPLVYYNMRMBNGE-UHFFFAOYSA-N Eponemycin Natural products CC(C)CCCCC(=O)NC(CO)C(=O)NC(CC(C)=C)C(=O)C1(CO)CO1 ZPLVYYNMRMBNGE-UHFFFAOYSA-N 0.000 description 1
- 241000371997 Eriocheir sinensis Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 241000533950 Leucojum Species 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 108060003100 Magainin Proteins 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- MSHZHSPISPJWHW-PVDLLORBSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)NC(=O)CCl)C[C@@]21CO2 MSHZHSPISPJWHW-PVDLLORBSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229920002201 Oxidized cellulose Polymers 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 102100029532 Probable fibrosin-1 Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 241000192023 Sarcina Species 0.000 description 1
- 229920001872 Spider silk Polymers 0.000 description 1
- 108010034396 Streptogramins Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 235000004240 Triticum spelta Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- VSJVHFFAEGLOBH-UHFFFAOYSA-N [F].C1=CN=CN=C1 Chemical compound [F].C1=CN=CN=C1 VSJVHFFAEGLOBH-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009954 braiding Methods 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZPFKRQXYKULZKP-UHFFFAOYSA-N butylidene Chemical group [CH2+]CC[CH-] ZPFKRQXYKULZKP-UHFFFAOYSA-N 0.000 description 1
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960004350 cefapirin Drugs 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 1
- 229960005229 ceftiofur Drugs 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229920003020 cross-linked polyethylene Polymers 0.000 description 1
- 239000004703 cross-linked polyethylene Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000010891 electric arc Methods 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- ZPLVYYNMRMBNGE-TWOQFEAHSA-N eponemycin Chemical compound CC(C)CCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)=C)C(=O)[C@@]1(CO)CO1 ZPLVYYNMRMBNGE-TWOQFEAHSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000019305 fibroblast migration Effects 0.000 description 1
- 108010093597 fibrosin Proteins 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960000618 fluprednisolone Drugs 0.000 description 1
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
- 229960000936 fumagillin Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000008271 glucosaminides Chemical class 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011490 mineral wool Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229940017578 naxcel Drugs 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 239000010955 niobium Substances 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940107304 oxidized cellulose Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960002858 paramethasone Drugs 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108010019657 polymyxin drug combination nystatin neomycin dimethicone acetarsol Proteins 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000909 polytetrahydrofuran Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical group [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 229930185107 quinolinone Natural products 0.000 description 1
- 108010071077 quinupristin-dalfopristin Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- 229960005256 sulbactam Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940020707 synercid Drugs 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 150000003481 tantalum Chemical class 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- 229950001139 timonacic Drugs 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
- A61B17/06166—Sutures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
- A61B17/06195—Apparatus or means for preparing the cut end of the suture thread to be attached to the needle, e.g. tipping to prevent brooming
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/0469—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery
- A61B2017/0477—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery with pre-tied sutures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B2017/0496—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials for tensioning sutures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
- A61B17/06166—Sutures
- A61B2017/06176—Sutures with protrusions, e.g. barbs
Abstract
本公开提供了一种包括具有锥形表面的环的缝合线。该缝合线包括具有近侧部分和远侧部分的细长体,其中,远侧部分包括第一和第二重叠区域以及环。第一重叠区域的近侧端可以相对于细长体的纵轴逐渐变细。第一重叠区域可以在环的近侧固定于第二重叠区域上。所述重叠区域可以通过选自胶、粘合剂、环氧化合物、溶剂、热和超声能量中的至少一种方法固定在一起。
Description
相关申请的交叉参考
本申请要求于2008年9月11日提交的序列号为61/096,145的美国临时申请的权利和优先权,其全部内容在此引入作为参考。
技术领域
本公开涉及一种具有环的缝合线。更具体而言,本公开涉及一种具有锥形表面的有环缝合线。
背景技术
包括在其中形成的环的缝合线是已知的。制造过程中形成于缝合线中的环可用于将缝合线固定于组织上。不管形成环的原因,在缝合线中形成环时,不管是否使用粘合剂、热或者超声能量,在两个缝合线部分重叠的地方,缝合线的直径都要加倍。在缝合线环用于固定组织的情况下,为产生环而使缝合线直径加倍会使得将环拉过组织所需的力量增大。这种施加于缝合线上的增大的力会导致缝合组织撕开或其它不必要的损伤。因此,提供一种包括锥形表面的有环缝合线以及制备这种缝合线的方法将是有益的。
发明内容
本公开提供了一种包括具有锥形表面的环的缝合线。该缝合线包括具有近侧部分和远侧部分的细长体,其中,细长体的远侧部分包括第一和第二重叠区域以及环。第一重叠区域的近侧端可以包括相对于细长体的纵轴逐渐变细的锥形表面。第一重叠区域可以在环的近侧固定于细长体上。所述重叠区域可以通过选自胶、粘合剂、环氧化合物、溶剂、热和超声能量中的至少一种方法固定在一起。
重叠区域可以使用超声能量熔接在一起。作为替代,可以使用粘合剂将重叠区域粘合在一起。锥形表面可以是基本上直线的或者弯曲的。弯曲可以是凸起的或者凹入的。锥形表面朝向细长体的纵轴可以向下弯曲形成角度。可以使环具有一定大小和尺寸以容纳细长体的长度。可以使环具有一定大小和尺寸以容纳外科手术针。
缝合线可以进一步包括附在细长体的近侧端上的外科手术针。细长体可以包括在其至少一部分上的倒刺。环可以包括在其至少一部分上的倒刺。可以将锥形表面形成为穿过组织的形状。锥形表面相对于细长体的纵轴可以形成的角度为大约0°~大约90°,优选大约5°~大约60°。缝合线可以选自单丝和多丝。
本公开还提供了一种使用包括锥形表面的有环缝合线的方法。该方法包括如下步骤:提供缝合线,该缝合线包括细长体和在该细长体远侧端形成的环,其中至少一部分细长体固定于重叠区域并且重叠区域的近侧端逐渐变细;将细长体的近侧端插入组织中;以及拉动细长体穿过组织直至锥形重叠区域与组织接合。
所述方法进一步包括将细长体的近侧端插入并穿过环的步骤。缝合线可以包括附在细长体的近侧端上的针。所述方法还可以包括将细长体的近侧端穿过环拉紧直至组织被保留在缝合线中的步骤。
附图说明
附图包括于本说明书中并构成说明书的一部分,其解释了本公开的实施方式,并与上面提供的本公开的一般描述以及下面提供的实施方式的详细描述一起用于解释本公开的原理,其中:
图1为根据本公开一个实施方式的有环缝合线的侧视图;
图1A为根据本公开另一个实施方式的有环缝合线的侧视图;
图2为沿图1线2-2截取的有环缝合线的截面端视图;
图3为图1的部分3的放大侧视图;
图4A-4F为具有圆形(4A)、椭圆形(4B)、矩形(正方形)(4C)、扁平形(4D)、八边形(4E)和长方形(4F)截面轮廓的丝线的透视图;
图5A-5C为本公开的有环缝合线的一个替代实施方式的视图;
图6A-6C为本公开的有环缝合线的又一实施方式的视图;
图7A-7C为本公开的有环缝合线的再一实施方式的视图。
具体实施方式
如图1所示,根据本公开的缝合线的实施方式一般性地被显示为有环缝合线10。缝合线10由单丝丝线11形成,然而,可以想象缝合线10可以由编织丝线、多丝丝线和其它外科手术纤维形成。
虽然示出了具有圆形截面几何形状的丝线11,但是其截面几何形状可以是任意合适形状。例如,图4A-4F示出了丝线11多种截面几何形状的替代实施方式的截面视图,即,圆形(4A)、椭圆形(4B)、正方形(4C)、扁平形(4D)、八边形(4E)和长方形(4F)。
丝线11可以由可降解材料、非可降解材料或者其组合形成。更具体而言,丝线11可以由选自聚酯、聚原酸酯、聚合物药物、聚羟基丁酸酯、内酯、蛋白质、肠线、胶原、碳酸酯、其均聚物、其共聚物及其组合中的可降解材料形成。在其它实施方式中,可以用于形成丝线11的合适的可降解材料包括天然胶原材料或者合成树脂,该合成树脂包括源自如亚丙基二碳酸酯、亚丁基二碳酸酯等的亚烷基碳酸酯;己内酯;二噁烷酮;乙醇酸;乳酸;其均聚物;其共聚物;以及其组合中的那些。在一些实施方式中,基于乙交酯和丙交酯的聚酯,尤其是乙交酯和丙交酯的共聚物可以用于形成丝线11。
可以用于形成丝线11的合适的非可降解材料包括聚烯烃,如聚乙烯和聚丙烯;聚乙烯和聚丙烯的共聚物,以及聚乙烯和聚丙烯的混合物;聚酰胺(如尼龙);聚胺;聚亚胺;聚酯,如聚对苯二甲酸乙二酯;聚四氟乙烯;聚醚-酯,如聚丁酯;聚四亚甲基醚乙二醇;1,4-丁二醇;聚氨酯;及其组合。其它合适的非可降解材料包括蚕丝、棉花、亚麻、碳纤维等。所述聚丙烯可以是全同立构聚丙烯,或者全同立构和间同立构或者无规立构聚丙烯的混合物。
可以使用本领域技术人员视界范围内的任何技术,如,例如挤压、模塑和/或纺纱来形成丝线11。在一些实施方式中,丝线11可以包括由超过一种的纤丝制成的纱线,其可以包括相同或者不同材料的多种纤丝。在丝线11由多种纤丝制成时,可以使用,如,例如编织、纺织或者针织的任何已知技术制成丝线11。还可以组合丝线11以产生无纺缝合线。作为缝合线形成过程的一部分,可以拉伸、取向、卷曲、扭曲、掺合或者喷气缠结丝线11以形成纱线。在一个实施方式中,可以通过编织产生多丝缝合线。可以通过本领域技术人员视界范围内的任何方法来进行编织。
仍然参照图1,有环缝合线10包括在其远侧端10b上形成的环12。有环缝合线10的近侧端10a可以包括一个或者多个缝合针(未示出)。环12形成基本上为泪珠的形状并且可以是任何大小。在一个实施方式中,可以使环12具有容纳有环缝合线10的近侧端10a的大小。单丝丝线11的第一区域13与丝线11的第二区域14重叠以形成环12。第一和第二区域13、14的相邻表面形成接合区域或者接合点15。
在一个实施方式中,如2008年9月24日提交的美国临时申请第61/099,594号中所公开的,将丝线11的第一和第二区域13、14熔接在一起,该申请的全部内容在此引入作为参考。依此方式,将丝线11的第一和第二区域13、14进行局部加热直至各自熔化以形成熔接区域15。可以使用各种类型的能量来局部加热第一和第二区域13、14以形成接合区域15,其包括无线电频率(RF)、超声、激光、电弧放电和热。作为替代,可以使用胶、环氧化合物、溶剂或者其它粘合剂将丝线11的第一和第二区域13、14接合。
具体参考图3,使第一区域13的近侧端13a弯曲形成一定角度以形成锥形表面17。锥形表面17朝向有环缝合线10的近侧端10a向下弯曲成一定角度。锥形表面17相对于第二区域14的纵轴“X”形成的角度α在零度(0°)至九十度(90°)之间,优选在大约五度(5°)至大约六十度(60°)之间。锥形表面17有利于环12插入或者穿过组织。锥形表面17可以在接合第一和第二区域13、14之前、期间或者之后形成。在一个实施方式中,在熔接过程中使用具有切割表面(未示出)的模具(未示出)形成锥形表面17。在另一个实施方式中,使用刀片(未示出)形成锥形表面17。可以将用于形成锥形表面17的刀片用加热、超声振动或者其它可以采用的方式进行处理以有利于丝线11的切割。可以以接合区域15延伸超过丝线11的第一区域13的方式形成第一区域13的锥形表面17。以此方式,锥形表面17与丝线11的第二区域14形成平坦过渡,从而降低了在有环缝合线10被拉动穿过组织时第一和第二区域13、14可能彼此分离或者剥离的可能性。
虽然示出的为具有基本上平坦的锥形的锥形表面,但是锥形表面17可以包括多种构型。例如,图5A-7C示出了替代实施方式,包括斜面锥形表面17a(图5A-5C)、横向和纵向凹入锥形表面17b(图6A-6C)、横向和纵向凸起锥形表面17c(图7A-7C)或者其任意组合。各斜面、凹入和凸起锥形表面(共同地,具有特定形状的锥形表面17a-c)可以以与平坦锥形表面17相似的方式形成。换句话说,可以在熔接过程中使用具有合适形状切割表面(未示出)的模具(未示出)形成具有特定形状的锥形表面17a-c。作为替代,可以使用具有合适形状的切割表面的刀片(未示出)形成具有特定形状的锥形表面17a-c。可以根据被缝合的组织和/或环12需要在组织中穿入的深度来选择锥形表面17。
反过来简述图1A,有环缝合线10可以包括在其中形成的倒刺3和其它突起。倒刺3可以以任何合适的图案,例如螺旋、直线排列或者无规间隔开。该图案可以是对称的或者不对称的。倒刺3的数目、构型、间隔和表面积可以根据缝合线10所用于的组织,以及丝线11的材料组成和几何形状来选择。另外,倒刺3的比例可以保持相对衡定,而倒刺3的总长度和倒刺3的间隔可以由要连接的组织来确定。例如,如果缝合线10用于连接皮肤或者腱中伤口的边缘,制成的倒刺3可以相对短并且更刚硬以有利于进入这种相对结实的组织。或者,如果缝合线10打算用于相对软的脂肪组织,制成的倒刺可以更长且间隔更远以提高缝合线10抓紧软组织的能力。
倒刺3的表面积也可以改变。例如,可以制成设计用于特定外科手术应用的多种尺寸的圆头倒刺。为了接合脂肪和相对软的组织,会需要较大的倒刺,而较小的倒刺可更适合用于胶原丰富的组织。在一些实施方式中,相同结构的大和小的倒刺的组合将是有益的,例如当缝合线用于具有不同层结构的组织修复时。在相同的缝合线中使用大和小倒刺的组合(其中倒刺尺寸根据各个组织层定制)将确保最大的锚固性质。在特殊实施方式中,单方向缝合线会既具有大倒刺也具有小倒刺,在其它实施方式中,双方向缝合线会既具有大倒刺也具有小倒刺。倒刺3可以包括如圆形、三角形、正方形、倾斜的、椭圆形、八角形、长方形和扁平形的几何形状。在一些实施方式中,倒刺3在环12上形成,其可以允许环12在一个方向上移动穿过组织,但是在环12被植入组织中后其又阻挡缝合线10的抽回。
当由可降解材料制备时,取决于使用的具体共聚物的性质,缝合线10在植入后会保持其结构整体性一段预定的时间。例如,这种性质包括共聚物的成分(既包括用于形成共聚物的单体又包括任何加入的添加剂),以及处理条件(例如,共聚合反应速度,反应温度、压力等)和对所得共聚物进行的任何进一步处理,例如涂敷、消毒等。环12形成中涉及的制备参数同样影响缝合线10吸收的速度。接合区域15可以从缝合线10中以不同的速度吸收。
如于2006年11月2日提交的名称为“Long Term Bioabsorbable BarbedSutures(长期生物可吸收带刺缝合线)”的美国专利申请第11/556,002号中所描述的,在缝合线主体上形成倒刺3(图1A)可以用于改变缝合线10的降解时间,该申请的全部内容在此作为参考引入。
有环缝合线10可以用一种或者多种医疗外科手术可用的物质涂敷或者浸渍,该物质在将缝合线10用于伤口或者手术部位时可以加速或者有利地改善愈合过程。在某些实施方式中,可由选择如下物质的可降解聚合物形成涂层:内酯、碳酸酯、聚原酸酯、羟基链烷酸酯、羟基丁酸酯、生物活性剂、聚酐、聚硅氧烷、硬酯酰乳酸钙、乙烯基聚合物、高分子量蜡和油、天然聚合物、蛋白质、多糖、可悬浮粒子、可分散粒子、微球、纳米球、棒状物、其均聚物、其共聚物及其组合。
合适的生物活性剂包括,例如杀生物剂、抗菌剂、抗生素、抑制细胞增殖剂、药剂、生长因子、抗凝剂、凝结剂、止痛剂、麻醉剂、抗炎剂、伤口修复剂等、化学治疗剂、生物制剂、蛋白治疗剂、单克隆或者多克隆抗体、DNA、RNA、肽、多糖、凝集素、脂质、益生菌、诊断剂、血管新生剂、抗血管新生药物、聚合物药物及其组合。
生物活性剂包括对愈合过程有益并促进愈合过程的物质。例如,可以向缝合线10提供沉积在缝合部位的生物活性剂。可以根据其抗菌性质、促进伤口恢复和/或组织生长的能力,或者根据如血栓形成的具体指征,选择生物活性剂。在实施方式中,可以在倒刺3形成之前、过程中或者之后将这种试剂的组合应用于本公开的医学器件。
本文中使用的术语“抗菌剂”包括通过其自身或者通过辅助免疫系统帮助身体杀死或者抵抗可能是致病性的微生物的试剂。抗菌剂包括抗生素、防腐剂、细菌群体感应阻断剂、抗真菌剂、抗病毒剂、表面活性剂、金属离子、抗菌蛋白和肽、抗菌多糖、消毒剂及其组合。可以以此方式应用缓慢释放进组织中的抗菌剂以有助于抵抗在外科手术或者外伤伤口部位的临床和亚临床感染。在实施方式中,合适的抗菌剂可以溶于一种或者多种溶剂。
在实施方式中,可以单独或者与本文中描述的其它生物活性剂组合使用下述生物活性剂:蒽环类抗生素、阿霉素、米托蒽醌、氟嘧啶、叶酸拮抗剂、甲氨蝶呤、米托蒽醌、细菌群体感应阻断剂、溴化或者卤化呋喃酮、鬼臼毒素、依托泊苷、喜树碱、羟基脲、铂复合物、顺铂、强力霉素、甲硝唑、甲氧苄啶-磺胺甲噁唑、如利福平的利福霉素、第四代青霉素(例如,脲基青霉素、羧基青霉素、磺唑氨苄青霉素、氧哌嗪青霉素、羧苄青霉素、羧噻吩青霉素钠、及其类似物或者衍生物)、第一代头孢菌素(例如,头孢唑啉钠、头孢氨苄、头孢唑啉、头孢匹林和头孢噻吩)、羧基青霉素(例如,替卡西林)、第二代头孢菌素(例如,头孢呋辛、头孢替坦和头孢西丁)、第三代头孢菌素(例如,头孢噻呋(naxcel)、头孢地尼、头孢哌酮、头孢他啶、头孢曲松和头孢噻肟)、聚乙烯吡咯烷酮(PVP)、第四代头孢菌素(例如,头孢吡肟)、单酰胺菌素(例如,氨曲南)、碳青霉烯类抗生素(例如,亚胺培南、厄他培南(ertapenem)和美罗培南)、氨基葡糖苷(例如,链霉素、庆大霉素、妥布霉素和阿米卡星)、MSL组成员(例如,大环内酯、长效大环内酯、林肯酰胺、链霉杀阳菌素、红霉素、阿奇霉素、氯林肯霉素、共杀素(Syneroid)、克拉霉素和硫酸卡那霉素)、如米诺环素的四环素、夫西地酸、甲氧苄啶、甲硝唑、喹诺酮(例如,环丙沙星、氧氟沙星、加替沙星、莫西沙星、左氧氟沙星和曲伐沙星)、DNA合成抑制剂(例如,甲硝唑)、磺胺(例如,磺胺甲噁唑、甲氧苄啶、包括头孢克肟、大观霉素、四环素、呋喃妥因、多粘霉素B和硫酸新霉素)、如舒巴坦的β-内酰胺抑制剂、氯霉素、如万古霉素的糖肽、莫匹罗星、如两性霉素B的多烯、如氟康唑的吡咯、及其它本领域已知的抗菌剂。
其它合适的生物活性剂包括下列物质中的一种或者多种:促进细胞再生的纤维化剂、促进血管生成的纤维化剂、促进成纤维细胞迁移的纤维化剂、促进成纤维细胞增殖的纤维化剂、促进细胞外基质沉积的纤维化剂、促进组织再造的纤维化剂、为憩室壁刺激剂的纤维化剂、丝(例如蚕丝、蜘蛛丝、重组体丝、生丝、水解丝、酸处理丝和酰化丝)、滑石、壳聚糖、博来霉素或其类似物或者衍生物、结缔组织生长因子(CTGF)、金属铍或者其氧化物、铜、八叠球菌(saracin)、二氧化硅、结晶硅酸盐、石英粉、滑石粉、乙醇、细胞外基质的成分、氧化纤维素、多糖、胶原、纤维蛋白、纤维蛋白原、聚(对苯二甲酸二乙醇酯)、聚(乙烯-共-乙酸乙烯酯)、N-羧丁基壳聚糖、RGD蛋白质、氯乙烯聚合物、氰基丙烯酸酯、交联聚乙二醇-甲基化胶原、炎性细胞因子、TGFβ、PDGF、VEGF、TNFa、NGF、GM-CSF、IGF-a、IL-1、IL-8、IL-6、生长激素、成骨蛋白、细胞增殖剂、地塞米松、异维A酸、17-β雌二醇、雌二醇、己烯雌酚、环胞素a、全-反-视黄酸或者其类似物或者衍生物、毛(包括动物毛、刨花和矿棉)、棉、bFGF、聚氨酯、聚四氟乙烯、活化素、血管生成素、类胰岛素生长因子(IGF)、肝细胞生长因子(HGF)、集落刺激因子(CSF)、促红细胞生成素、干扰素、内皮素-1、血管紧张素II、溴麦角环肽、二甲麦角新碱、丝蛋白(fibrosin)、纤维蛋白、黏着糖蛋白、蛋白聚糖、透明质烷、富含半胱氨酸的酸性分泌蛋白(SPaRC)、凝血酶敏感蛋白、粘合素(tenacin)、细胞粘着分子、基于葡聚糖的粒子、基质金属蛋白酶抑制剂、马加宁、组织或肾纤溶酶原活化因子、基质金属蛋白酶组织抑制剂、四氯化碳、硫代乙酰胺、用于清除组织损伤自由基的超过氧化物歧化酶、用于癌症治疗的肿瘤坏死因子、集落刺激因子、干扰素、用于增强免疫系统的白细胞介素-2或其它淋巴因子、富血小板血浆、凝血酶、如自组装肽系统的肽、如基于radA的氨基酸的氨基酸、如超强吸水凝胶材料的水凝胶、及其组合等。
多种抗血管新生因子可易于用于本公开的范围内。典型实例包括抗侵入(anti-lnvasive)因子;视黄酸及其衍生物;高衍生二萜类化合物紫杉醇;舒拉明;金属蛋白酶-1组织抑制剂;金属蛋白酶-2组织抑制剂;纤溶酶原激活物抑制剂-1;纤溶酶原激活物抑制剂-2;例如钒、钼、钨、钛、铌和钽系列的较轻“d族”过渡金属的多种形式及其复合物;血小板因子4;硫酸鱼精蛋白(鲱精蛋白);硫酸化甲壳质衍生物(由雪花蟹壳制备);硫酸化多糖肽聚糖复合物(SP-PG)(该化合物的作用可通过例如雌激素和枸橼酸他莫昔芬的类固醇的存在而增强);星状孢子素;基质代谢调节剂,包括例如脯氨酸类似物{[(L-铃兰氨酸(LACA)、顺羟基脯氨酸(cishydroxyproline)、d,L-3,4-脱氢辅氨酸、硫代脯氨酸(Thiaproline)、α,α-联吡啶、β-氨基丙腈反丁烯二酸酯]};MDL 27032(4-丙基-5-(4-吡啶基)-2(3H)-噁唑酮;甲氨蝶呤;米托蒽醌;肝素;干扰素类;2巨球蛋白血清;ChlMP-3;糜蛋白酶抑制素;β-环糊精十四烷基硫酸酯;依匹霉素(Eponemycin);喜树碱;烟曲霉素硫代苹果酸金钠(“GST”);D-青霉胺(“CDPT”);β-1-抗胶原酶-血清;α2-抗纤维蛋白溶酶;比生群;氯苯扎利二钠(N-(2)-羧基苯基-4-氯代氨茴酸二钠(N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium)或者“CCA”;沙立度胺;抑制血管生成的类固醇(Angostatic steroid);AGM-1470;羧基氨基咪唑(carboxynaminolmidazole);例如BB94的金属蛋白酶抑制剂、其类似物及衍生物;及其结合。
多种聚合物药物可易于用于本公开的范围内。代表性实例包括类固醇抗炎剂、非类固醇抗炎剂、及其结合。可用于本公开的非类固醇抗炎剂的实例为阿司匹林、吲哚美辛、布洛芬、保泰松、二氟西诺(diflusinal)、及其结合。
可使用的类固醇抗炎剂的实例为糖皮质激素,例如可的松和氢化可的松、倍他米松、地塞米松、氟泼尼龙、泼尼松、甲基泼尼松龙、泼尼松龙、氟羟泼尼松龙、帕拉米松、及其结合。
虽然为了举例说明的目的,已经提供了上述生物活性剂,但是应该理解本公开不限制于此。特别是,虽然以上明确指出了某些生物活性剂,但是应该理解本公开包括这些试剂的类似物、衍生物和结合物。
缝合线10也可以包括例如,生物可接受的增塑剂、抗氧化剂和着色剂,其可以渗入用于形成本公开的缝合线的纤丝中或者包含于其上的涂层里。
可以使用本领域技术人员范围内的任何方法,例如,浸渍、喷涂、蒸汽沉积、刷、溶剂蒸发、混合等将生物活性剂涂敷到缝合线10上。在实施方式中,生物活性剂可以沉积在倒刺角,即倒刺3与丝线11之间形成的角中。位于倒刺3与丝线11之间形成的角中使生物活性剂位于组织伤口闭合中精确限定的位置,从而提供一种独特的控制并持续释放的用药形式。
为了提高缝合线10在外科手术领域的可见性,可以将丝线11染色。可以使用任何适于掺入医学器件中的染料。这种染料包括但不限于碳黑、骨炭、D&C绿色NO.6以及D&C紫色NO.2。可以通过加入最高至大约几个百分比的量的染料来将根据本公开的纤丝染色,在其它实施方式中,可以通过加入大约0.2%的量的染料来将它们染色,在又一实施方式中,可以加入大约0.06%至0.08%的量的染料。
在使用中,有环缝合线10包括附在其近侧端10a上的针(未示出)。该针被插入并穿过组织的第一和第二瓣。拉动有环缝合线10穿过组织直至第一区域13的近侧端13a接触组织。继续拉动缝合线10的近侧端10a以使锥形近侧端13a与组织接合。近侧端13a的锥形表面17使缝合线10的重叠区域以降低的阻力容纳在组织中,从而使对组织的损伤最小化。一旦缝合线10的环12的一部分容纳于组织中,将缝合线10的近侧端10a插入并穿过环12。然后可以拉紧缝合线10的近侧端10a,从而使彼此朝向的第一和第二组织瓣靠近。然后可以将缝合线10的近侧端10a打结或者固定于环12上。在一个实施方式中,可以在近侧端10a形成结以防止近侧端10a被从环12中抽回。在另一实施方式中,缝合线10的近侧端10a可以被直接系到环12上。
虽然本文参考附图已经描述了本公开的说明性实施方式,但是应该理解,本公开并不限于这些具体的实施方式,并且在不偏离本公开的范围和实质的情况下,本领域技术人员所做的各种其它改变或者改进在本文中是有效的。
Claims (24)
1、一种缝合线,其包括:
包括近侧部分和远侧部分的细长体,其中,该远侧部分包括第一和第二重叠区域以及环。
2、根据权利要求1所述的缝合线,其中,所述第一重叠区域的近侧端包括锥形表面,该锥形表面相对于所述细长体的纵轴逐渐变细。
3、根据权利要求1所述的缝合线,其中,所述第一重叠区域在所述环的近侧固定于所述第二重叠区域上。
4、根据权利要求1所述的缝合线,其中,所述第一和第二重叠区域通过选自胶、粘合剂、溶剂、环氧化合物、热和超声能量中的至少一种方法固定在一起。
5、根据权利要求2或3所述的缝合线,其中,所述第一和第二重叠区域通过使用超声能量熔接在一起。
6、根据权利要求1所述的缝合线,其中,所述重叠区域使用粘合剂粘合在一起。
7、根据权利要求2所述的缝合线,其中,所述锥形表面是基本上直线的。
8、根据权利要求2所述的缝合线,其中,所述锥形表面是基本上弯曲的。
9、根据权利要求8所述的缝合线,其中,所述弯曲为凸起的。
10、根据权利要求8所述的缝合线,其中,所述弯曲为凹入的。
11、根据权利要求2所述的缝合线,其中,所述锥形表面朝向所述细长体的纵轴向下弯曲形成角度。
12、根据权利要求1所述的缝合线,其中,使所述环具有一定大小和尺寸以容纳所述细长体的长度。
13、根据权利要求1所述的缝合线,其中,使所述环具有一定大小和尺寸以容纳外科手术针。
14、根据权利要求1所述的缝合线,其进一步包括附在所述细长体的近侧端外科手术针。
15、根据权利要求1所述的缝合线,其中,所述细长体包括在其至少一部分上的倒刺。
16、根据权利要求1所述的缝合线,其中,所述环包括在其至少一部分上的倒刺。
17、根据权利要求2所述的缝合线,其中,所述锥形表面被形成为穿过组织的形状。
18、根据权利要求2所述的缝合线,其中,所述锥形表面相对于所述细长体的纵轴形成的角度为约0°~约90°。
19、根据权利要求2所述的缝合线,其中,所述锥形表面形成的角度为约5°~约60°。
20、根据权利要求1所述的缝合线,其中,所述缝合线选自单丝和多丝丝线中。
21、一种使用包括锥形表面的有环缝合线的方法,该方法包括如下步骤:
提供缝合线,该缝合线包括细长体和在该细长体远侧端形成的环,其中至少一部分细长体固定于重叠区域并且重叠区域的近侧端逐渐变细;
将细长体的近侧端插入组织中;以及
拉动细长体穿过组织直至锥形重叠区域与组织接合。
22、根据权利要求21所述的方法,其进一步包括将所述细长体的近侧端插入并穿过所述环的步骤。
23、根据权利要求21所述的方法,其中,所述缝合线包括附在细长体的近侧端上的针。
24、根据权利要求22所述的方法,其进一步包括将所述细长体的近侧端穿过所述环拉紧直至组织被保留在所述缝合线中的步骤。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9614508P | 2008-09-11 | 2008-09-11 | |
US61/096,145 | 2008-09-11 | ||
US12/548,594 | 2009-08-27 | ||
US12/548,594 US10016196B2 (en) | 2008-09-11 | 2009-08-27 | Tapered looped suture |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101683278A true CN101683278A (zh) | 2010-03-31 |
CN101683278B CN101683278B (zh) | 2014-07-16 |
Family
ID=41404283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910171682.1A Active CN101683278B (zh) | 2008-09-11 | 2009-09-07 | 锥形有环缝合线 |
Country Status (6)
Country | Link |
---|---|
US (3) | US10016196B2 (zh) |
EP (3) | EP2540229B1 (zh) |
JP (2) | JP5646832B2 (zh) |
CN (1) | CN101683278B (zh) |
AU (1) | AU2009212980B2 (zh) |
CA (1) | CA2678277C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102666956A (zh) * | 2010-06-09 | 2012-09-12 | 韩国美塔生物材料株式会社 | 手术用缝合丝的制备方法 |
CN102988090A (zh) * | 2012-12-20 | 2013-03-27 | 中南大学湘雅医院 | 一种半月板损伤手术缝合线 |
CN103096816A (zh) * | 2010-05-04 | 2013-05-08 | 伊西康有限责任公司 | 用于产生自固位缝线的激光切割系统和方法 |
CN104739464A (zh) * | 2013-05-31 | 2015-07-01 | 高立彦 | 含有可变环的带倒刺手术缝合线 |
CN107920816A (zh) * | 2015-09-04 | 2018-04-17 | 伊西康公司 | 用于伤口闭合装置的改进的端部执行器 |
CN114769473A (zh) * | 2022-06-22 | 2022-07-22 | 河北京南众康科技有限公司 | 一种倒刺缝合线尾环焊接多功能加工设备 |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6241747B1 (en) | 1993-05-03 | 2001-06-05 | Quill Medical, Inc. | Barbed Bodily tissue connector |
US8795332B2 (en) | 2002-09-30 | 2014-08-05 | Ethicon, Inc. | Barbed sutures |
US5931855A (en) | 1997-05-21 | 1999-08-03 | Frank Hoffman | Surgical methods using one-way suture |
US7056331B2 (en) | 2001-06-29 | 2006-06-06 | Quill Medical, Inc. | Suture method |
US6848152B2 (en) | 2001-08-31 | 2005-02-01 | Quill Medical, Inc. | Method of forming barbs on a suture and apparatus for performing same |
US6773450B2 (en) | 2002-08-09 | 2004-08-10 | Quill Medical, Inc. | Suture anchor and method |
US8100940B2 (en) | 2002-09-30 | 2012-01-24 | Quill Medical, Inc. | Barb configurations for barbed sutures |
US20040088003A1 (en) | 2002-09-30 | 2004-05-06 | Leung Jeffrey C. | Barbed suture in combination with surgical needle |
US7624487B2 (en) | 2003-05-13 | 2009-12-01 | Quill Medical, Inc. | Apparatus and method for forming barbs on a suture |
SG164370A1 (en) | 2004-05-14 | 2010-09-29 | Quill Medical Inc | Suture methods and devices |
US7909851B2 (en) | 2006-02-03 | 2011-03-22 | Biomet Sports Medicine, Llc | Soft tissue repair device and associated methods |
US7749250B2 (en) | 2006-02-03 | 2010-07-06 | Biomet Sports Medicine, Llc | Soft tissue repair assembly and associated method |
US8118836B2 (en) | 2004-11-05 | 2012-02-21 | Biomet Sports Medicine, Llc | Method and apparatus for coupling soft tissue to a bone |
US7905904B2 (en) | 2006-02-03 | 2011-03-15 | Biomet Sports Medicine, Llc | Soft tissue repair device and associated methods |
US8361113B2 (en) | 2006-02-03 | 2013-01-29 | Biomet Sports Medicine, Llc | Method and apparatus for coupling soft tissue to a bone |
US8128658B2 (en) | 2004-11-05 | 2012-03-06 | Biomet Sports Medicine, Llc | Method and apparatus for coupling soft tissue to bone |
US9017381B2 (en) | 2007-04-10 | 2015-04-28 | Biomet Sports Medicine, Llc | Adjustable knotless loops |
US8303604B2 (en) | 2004-11-05 | 2012-11-06 | Biomet Sports Medicine, Llc | Soft tissue repair device and method |
US8088130B2 (en) | 2006-02-03 | 2012-01-03 | Biomet Sports Medicine, Llc | Method and apparatus for coupling soft tissue to a bone |
US8652171B2 (en) | 2006-02-03 | 2014-02-18 | Biomet Sports Medicine, Llc | Method and apparatus for soft tissue fixation |
US8801783B2 (en) | 2006-09-29 | 2014-08-12 | Biomet Sports Medicine, Llc | Prosthetic ligament system for knee joint |
US10517587B2 (en) | 2006-02-03 | 2019-12-31 | Biomet Sports Medicine, Llc | Method and apparatus for forming a self-locking adjustable loop |
US11259792B2 (en) | 2006-02-03 | 2022-03-01 | Biomet Sports Medicine, Llc | Method and apparatus for coupling anatomical features |
US8562645B2 (en) * | 2006-09-29 | 2013-10-22 | Biomet Sports Medicine, Llc | Method and apparatus for forming a self-locking adjustable loop |
US11311287B2 (en) | 2006-02-03 | 2022-04-26 | Biomet Sports Medicine, Llc | Method for tissue fixation |
US11259794B2 (en) | 2006-09-29 | 2022-03-01 | Biomet Sports Medicine, Llc | Method for implanting soft tissue |
US8821542B2 (en) | 2006-10-31 | 2014-09-02 | Depuy Mitek, Llc | Suture management system |
US8915943B2 (en) | 2007-04-13 | 2014-12-23 | Ethicon, Inc. | Self-retaining systems for surgical procedures |
US8777987B2 (en) | 2007-09-27 | 2014-07-15 | Ethicon, Inc. | Self-retaining sutures including tissue retainers having improved strength |
US8916077B1 (en) | 2007-12-19 | 2014-12-23 | Ethicon, Inc. | Self-retaining sutures with retainers formed from molten material |
US8771313B2 (en) | 2007-12-19 | 2014-07-08 | Ethicon, Inc. | Self-retaining sutures with heat-contact mediated retainers |
US8118834B1 (en) | 2007-12-20 | 2012-02-21 | Angiotech Pharmaceuticals, Inc. | Composite self-retaining sutures and method |
US8615856B1 (en) | 2008-01-30 | 2013-12-31 | Ethicon, Inc. | Apparatus and method for forming self-retaining sutures |
EP2242430B1 (en) | 2008-01-30 | 2016-08-17 | Ethicon, LLC | Apparatus and method for forming self-retaining sutures |
WO2009105663A2 (en) | 2008-02-21 | 2009-08-27 | Angiotech Pharmaceuticals, Inc. | Method and apparatus for elevating retainers on self-retaining sutures |
US8216273B1 (en) | 2008-02-25 | 2012-07-10 | Ethicon, Inc. | Self-retainers with supporting structures on a suture |
US8641732B1 (en) | 2008-02-26 | 2014-02-04 | Ethicon, Inc. | Self-retaining suture with variable dimension filament and method |
JP5619726B2 (ja) | 2008-04-15 | 2014-11-05 | エシコン・エルエルシーEthicon, LLC | 双方向リテーナ又は一方向リテーナを持つ自己保持縫合材 |
US8961560B2 (en) | 2008-05-16 | 2015-02-24 | Ethicon, Inc. | Bidirectional self-retaining sutures with laser-marked and/or non-laser marked indicia and methods |
US10016196B2 (en) | 2008-09-11 | 2018-07-10 | Covidien Lp | Tapered looped suture |
US20100204729A1 (en) * | 2008-09-11 | 2010-08-12 | Ahmad Robert Hadba | Tapered Looped Suture |
AU2009319965B2 (en) | 2008-11-03 | 2014-11-06 | Ethicon Llc | Length of self-retaining suture and method and device for using the same |
US20110238111A1 (en) | 2010-03-28 | 2011-09-29 | Frank Joshua B | Soft Tissue Fixation Using A Looped Suture Construct |
US8968362B2 (en) | 2010-04-08 | 2015-03-03 | Covidien Lp | Coated looped suture |
CN103068323B (zh) | 2010-06-11 | 2015-07-22 | 伊西康有限责任公司 | 用于内窥镜式和机器人辅助式外科手术的缝合线递送工具 |
WO2012021600A1 (en) * | 2010-08-10 | 2012-02-16 | Tyco Healthcare Group Lp | Barbed implantable devices |
US20120083838A1 (en) | 2010-10-01 | 2012-04-05 | Tyco Healthcare Group Lp | Connectable End Effector |
US8398679B2 (en) | 2010-10-28 | 2013-03-19 | Covidien Lp | Modular suture |
CN103747746B (zh) | 2010-11-03 | 2017-05-10 | 伊西康有限责任公司 | 药物洗脱自固位缝合线及其相关方法 |
RU2580479C2 (ru) | 2010-11-09 | 2016-04-10 | ЭТИКОН ЭлЭлСи | Самоудерживающиеся шовные материалы для неотложной помощи и упаковки для них |
AU2012230716B2 (en) * | 2011-03-23 | 2016-05-19 | Ethicon Llc | Self-retaining variable loop sutures |
US20120245602A1 (en) * | 2011-03-23 | 2012-09-27 | Jonathan Glick | Welded Looped Suture |
US20130172931A1 (en) | 2011-06-06 | 2013-07-04 | Jeffrey M. Gross | Methods and devices for soft palate tissue elevation procedures |
US9357991B2 (en) | 2011-11-03 | 2016-06-07 | Biomet Sports Medicine, Llc | Method and apparatus for stitching tendons |
EP3245945B1 (en) * | 2011-11-07 | 2020-07-22 | ResMed Pty Ltd | Apparatus for providing ventilation to a patient |
US9381013B2 (en) | 2011-11-10 | 2016-07-05 | Biomet Sports Medicine, Llc | Method for coupling soft tissue to a bone |
US10336001B2 (en) * | 2015-09-04 | 2019-07-02 | Ethicon, Inc. | End effector for wound closure device |
US20190175170A1 (en) * | 2017-12-07 | 2019-06-13 | Arthrex, Inc. | Knotless closure suture and technique |
KR102182962B1 (ko) * | 2018-06-07 | 2020-11-26 | 메디퓨처스 주식회사 | 헤드부를 구비한 의료용 실 |
FR3101645B1 (fr) * | 2019-10-03 | 2021-10-15 | Faurecia Automotive Ind | Procédé de fabrication d’un revêtement intérieur bicolore pour véhicule automobile |
WO2021230900A1 (en) | 2020-05-15 | 2021-11-18 | Moliver Md Facs Clayton L | Knotless sutures including integrated closures |
WO2022031220A1 (en) * | 2020-08-05 | 2022-02-10 | I-Support Pte. Ltd. | Suture and system for cosmetic enhancement |
EP4241798A1 (en) * | 2022-03-11 | 2023-09-13 | Universidad de Granada | Hydrogel suitable to produce artificial tissues |
WO2024033763A1 (en) | 2022-08-10 | 2024-02-15 | Covidien Lp | Looped suture devices and methods of forming looped suture devices |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999052451A1 (en) * | 1998-04-16 | 1999-10-21 | Axya Medical, Inc. | Soft tissue fixation device |
US20020011508A1 (en) * | 1997-08-28 | 2002-01-31 | Egan Thomas D. | Fused constructs of filamentous material for surgical applications |
US20050267531A1 (en) * | 2004-05-14 | 2005-12-01 | Ruff Gregory L | Suture methods and devices |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2514184A (en) * | 1946-06-20 | 1950-07-04 | Firestone Tire & Rubber Co | Method of splicing thermoplastic monofilaments |
US3657056A (en) * | 1967-12-11 | 1972-04-18 | Ultrasonic Systems | Ultrasonic suturing apparatus |
US3513848A (en) * | 1967-12-11 | 1970-05-26 | Ultrasonic Systems | Ultrasonic suturing |
US3874963A (en) * | 1973-11-08 | 1975-04-01 | Kuss & Co R L | Sonic bonding process |
US4662068A (en) * | 1985-11-14 | 1987-05-05 | Eli Polonsky | Suture fusing and cutting apparatus |
US4950285A (en) * | 1989-11-27 | 1990-08-21 | Wilk Peter J | Suture device |
US5123913A (en) * | 1989-11-27 | 1992-06-23 | Wilk Peter J | Suture device |
US5002563A (en) * | 1990-02-22 | 1991-03-26 | Raychem Corporation | Sutures utilizing shape memory alloys |
US5259846A (en) * | 1991-01-07 | 1993-11-09 | United States Surgical Corporation | Loop threaded combined surgical needle-suture device |
US5226535A (en) * | 1992-02-14 | 1993-07-13 | Ethicon, Inc. | Package for endoscopic suture loop and cannula |
US5417700A (en) | 1992-03-30 | 1995-05-23 | Thomas D. Egan | Automatic suturing and ligating device |
US5383905A (en) * | 1992-10-09 | 1995-01-24 | United States Surgical Corporation | Suture loop locking device |
US5403331A (en) * | 1993-03-12 | 1995-04-04 | United States Surgical Corporation | Looped suture ligating device containing a heat-shrinkable element |
FR2729940B1 (fr) | 1995-01-31 | 1997-04-25 | Fyltis Sa | Dispositif de raccordement de deux fils monobrin |
JPH0952185A (ja) * | 1995-08-14 | 1997-02-25 | Yazaki Corp | 超音波溶着機 |
JPH09155979A (ja) | 1995-12-08 | 1997-06-17 | Meiwa Sangyo Kk | 高周波加熱を用いた溶着方法及びその装置 |
US5683417A (en) * | 1996-08-14 | 1997-11-04 | Cooper; William I. | Suture and method for endoscopic surgery |
US6730111B2 (en) | 1996-10-30 | 2004-05-04 | Semyon Shchervinsky | Surgical tipping apparatus |
US5830234A (en) * | 1997-04-04 | 1998-11-03 | Alto Development Corporation | Method for double wire sternotomy suture |
US5968077A (en) * | 1997-04-04 | 1999-10-19 | Alto Development Corporation | Double wire sternothomy suture |
US5893592A (en) | 1997-04-08 | 1999-04-13 | Ethicon Endo-Surgery, Inc. | Partially tied surgical knot |
KR100435257B1 (ko) * | 1997-08-07 | 2004-07-16 | 삼성전자주식회사 | 영상신호 처리 시스템에서의 이미지 포맷 변환장치 및 방법 |
US5893880A (en) * | 1997-08-28 | 1999-04-13 | Axya Medical Inc. | Fused loop filamentous material |
US6286746B1 (en) | 1997-08-28 | 2001-09-11 | Axya Medical, Inc. | Fused loop of filamentous material and apparatus for making same |
US6217591B1 (en) * | 1997-08-28 | 2001-04-17 | Axya Medical, Inc. | Suture fastening device |
WO1999026542A1 (en) | 1997-11-24 | 1999-06-03 | Axya Medical, Inc. | Suture fastening device |
FR2775595B1 (fr) * | 1998-03-09 | 2000-05-05 | Seppic Sa | Composition synergique comprenant un compose a structure lipoaminoacide et un extrait de menuphar |
US6409743B1 (en) * | 1998-07-08 | 2002-06-25 | Axya Medical, Inc. | Devices and methods for securing sutures and ligatures without knots |
US6174324B1 (en) * | 1998-07-13 | 2001-01-16 | Axya Medical, Inc. | Suture guide and fastener |
US6488690B1 (en) | 1999-03-17 | 2002-12-03 | John K. Morris | Suture knot sealing instruments and methods of using the same |
US6077277A (en) * | 1999-04-05 | 2000-06-20 | Starion Instruments, Inc. | Suture welding device |
US6436099B1 (en) * | 1999-04-23 | 2002-08-20 | Sdgi Holdings, Inc. | Adjustable spinal tether |
US6488890B1 (en) * | 1999-08-05 | 2002-12-03 | 3M Innovative Properties Company | Machine readable sterilization indicator for monitoring articles to be sterilized |
US6368343B1 (en) * | 2000-03-13 | 2002-04-09 | Peter M. Bonutti | Method of using ultrasonic vibration to secure body tissue |
US6547807B2 (en) * | 1999-12-03 | 2003-04-15 | Kwan-Ho Chan | Suture relay for surgery |
US6669705B2 (en) * | 2000-05-17 | 2003-12-30 | Axya Medical, Inc. | Apparatus and method for welding sutures |
AU2001280923A1 (en) | 2000-07-28 | 2002-03-26 | Axya Medical, Inc. | Fused constructs of filamentous material for surgical applications |
US7582097B2 (en) * | 2001-12-18 | 2009-09-01 | Ethicon, Inc. | Suture welding system and method |
US7007698B2 (en) * | 2002-04-03 | 2006-03-07 | Boston Scientific Corporation | Body lumen closure |
AU2003222660A1 (en) | 2002-04-18 | 2003-11-03 | Robert S. Langer | Biodegradable shape memory polymeric sutures |
US20040122451A1 (en) * | 2002-12-23 | 2004-06-24 | Wood Timothy J. | Method and device for closing and fusing suture loops |
US7021316B2 (en) * | 2003-08-07 | 2006-04-04 | Tools For Surgery, Llc | Device and method for tacking a prosthetic screen |
US7862583B2 (en) * | 2004-05-27 | 2011-01-04 | Ethicon Endo-Surgery, Inc. | Fusible suture and method for suturing therewith |
DE102004033575B3 (de) * | 2004-07-09 | 2006-04-13 | Schunk Ultraschalltechnik Gmbh | Anordnung zum Verschweißen von Werkstücken |
US8012202B2 (en) * | 2004-07-27 | 2011-09-06 | Alameddine Abdallah K | Mitral valve ring for treatment of mitral valve regurgitation |
DE602006019016D1 (de) * | 2005-03-30 | 2011-02-03 | Arthrex Inc | Hochfeste kettenartige Naht mit Schlaufen zur knotenlosen Befestigung |
EP2007289A2 (en) * | 2006-04-18 | 2008-12-31 | Axya Medical, Inc | Multicomponent fused suture loop and apparatus for making same |
US20080027468A1 (en) | 2006-07-27 | 2008-01-31 | Axya Medical Inc. | Suture needle, suture needle/suture assembly and suture passer device |
US20080281357A1 (en) * | 2007-05-09 | 2008-11-13 | An-Min Jason Sung | Looped tissue-grasping device |
DE102008009640A1 (de) * | 2008-02-18 | 2009-08-27 | Carl Zeiss Nts Gmbh | Prozessierungssystem |
US10376261B2 (en) * | 2008-04-01 | 2019-08-13 | Covidien Lp | Anchoring suture |
US9358002B2 (en) * | 2008-04-01 | 2016-06-07 | Covidien Lp | Anchoring device |
US20090259251A1 (en) * | 2008-04-11 | 2009-10-15 | Cohen Matthew D | Loop suture |
US7967841B2 (en) * | 2008-06-02 | 2011-06-28 | Ethicon, Inc. | Methods for using looped tissue-grasping devices |
US10016196B2 (en) | 2008-09-11 | 2018-07-10 | Covidien Lp | Tapered looped suture |
US8323316B2 (en) | 2008-10-09 | 2012-12-04 | Covidien Lp | Knotted suture end effector |
US8403017B2 (en) | 2008-10-27 | 2013-03-26 | Covidien Lp | System, method and apparatus for making tapered looped suture |
US9727727B2 (en) | 2014-09-26 | 2017-08-08 | Dropbox Inc. | Scanning content items based on user activity |
-
2009
- 2009-08-27 US US12/548,594 patent/US10016196B2/en active Active
- 2009-09-04 AU AU2009212980A patent/AU2009212980B2/en not_active Ceased
- 2009-09-07 CN CN200910171682.1A patent/CN101683278B/zh active Active
- 2009-09-09 CA CA2678277A patent/CA2678277C/en active Active
- 2009-09-10 JP JP2009208817A patent/JP5646832B2/ja not_active Expired - Fee Related
- 2009-09-11 EP EP12186217.1A patent/EP2540229B1/en active Active
- 2009-09-11 EP EP14163490.7A patent/EP2752160B1/en active Active
- 2009-09-11 EP EP09252170.7A patent/EP2163207B1/en active Active
-
2014
- 2014-01-27 JP JP2014012365A patent/JP2014094312A/ja not_active Withdrawn
-
2018
- 2018-06-13 US US16/006,886 patent/US10912552B2/en active Active
-
2021
- 2021-01-27 US US17/159,686 patent/US11812950B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020011508A1 (en) * | 1997-08-28 | 2002-01-31 | Egan Thomas D. | Fused constructs of filamentous material for surgical applications |
WO1999052451A1 (en) * | 1998-04-16 | 1999-10-21 | Axya Medical, Inc. | Soft tissue fixation device |
US20050267531A1 (en) * | 2004-05-14 | 2005-12-01 | Ruff Gregory L | Suture methods and devices |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103096816A (zh) * | 2010-05-04 | 2013-05-08 | 伊西康有限责任公司 | 用于产生自固位缝线的激光切割系统和方法 |
CN104706390A (zh) * | 2010-05-04 | 2015-06-17 | 伊西康有限责任公司 | 用于产生自固位缝线的激光切割系统和方法 |
CN103096816B (zh) * | 2010-05-04 | 2016-10-12 | 伊西康有限责任公司 | 用于产生自固位缝线的激光切割系统和方法 |
CN102666956A (zh) * | 2010-06-09 | 2012-09-12 | 韩国美塔生物材料株式会社 | 手术用缝合丝的制备方法 |
CN102988090A (zh) * | 2012-12-20 | 2013-03-27 | 中南大学湘雅医院 | 一种半月板损伤手术缝合线 |
CN104739464A (zh) * | 2013-05-31 | 2015-07-01 | 高立彦 | 含有可变环的带倒刺手术缝合线 |
CN107920816A (zh) * | 2015-09-04 | 2018-04-17 | 伊西康公司 | 用于伤口闭合装置的改进的端部执行器 |
CN107920816B (zh) * | 2015-09-04 | 2022-04-15 | 伊西康公司 | 用于伤口闭合装置的改进的端部执行器 |
CN114769473A (zh) * | 2022-06-22 | 2022-07-22 | 河北京南众康科技有限公司 | 一种倒刺缝合线尾环焊接多功能加工设备 |
Also Published As
Publication number | Publication date |
---|---|
EP2540229A1 (en) | 2013-01-02 |
EP2540229B1 (en) | 2014-04-09 |
US10016196B2 (en) | 2018-07-10 |
EP2752160B1 (en) | 2018-02-21 |
US10912552B2 (en) | 2021-02-09 |
CA2678277A1 (en) | 2010-03-11 |
EP2163207A1 (en) | 2010-03-17 |
US20100063540A1 (en) | 2010-03-11 |
EP2752160A1 (en) | 2014-07-09 |
US11812950B2 (en) | 2023-11-14 |
US20180289368A1 (en) | 2018-10-11 |
CA2678277C (en) | 2016-12-20 |
US20210145436A1 (en) | 2021-05-20 |
CN101683278B (zh) | 2014-07-16 |
EP2163207B1 (en) | 2013-07-31 |
JP2010063892A (ja) | 2010-03-25 |
AU2009212980A1 (en) | 2010-03-25 |
AU2009212980B2 (en) | 2015-05-21 |
JP2014094312A (ja) | 2014-05-22 |
JP5646832B2 (ja) | 2014-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101683278B (zh) | 锥形有环缝合线 | |
CN103315785B (zh) | 在缝合线上形成倒刺的方法 | |
CN102688073B (zh) | 复合倒刺式医疗装置及方法 | |
US10098633B2 (en) | Bioactive substance in a barbed suture | |
CA2734164A1 (en) | Coated looped suture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: American Connecticut Applicant after: Covidien LP Address before: American Connecticut Applicant before: TYCO Healthcare |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TYCO HEALTHCARE TO: COVIDIEN LP COMPANY |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |